Antibody Lead Generation
Accelerate the discovery of high‑affinity and diverse antibody leads.
Therapeutic Antibody Discovery Services
ProBio’s therapeutic antibody discovery services provide end‑to‑end support from early target validation to high‑quality preclinical candidates. Using diverse antibody generation platforms, advanced screening and characterization assays, and in‑house expertise in affinity, specificity, and developability optimization, ProBio helps accelerate the identification of robust antibody candidates tailored to your therapeutic goals.
Our Services & Solutions
We provide end‑to‑end support from early target validation to high‑quality preclinical candidates.
Discovery Platform Workflow
Target Discovery
Choosing the right target and strategy is the critical decision in your drug development
We provide comprehensive research and customized discovery strategy, based on your target and mechanism of action.
Lead Generation
Improve reliability, success rates, and cost-efficiency for lead generation
We use diverse technology (hybridoma, single B cell screening, phage display) to generate more high quality functional leads.
In Vitro Bioassay
Ensuring functional activity of selected leads for rapid project delivery
We provide a series of HTP cell-based in vitro assays, as part of a comprehensive cell line-based bioassay services offering.
Lead Optimization
Accelerating the discovery of effective antibody candidates via faster antibody engineering
We provide developability and functionality optimization through comprehensive engineering approaches and project experience.
In Vivo Validation
Gain critical understanding by evaluating preclinical candidates effectively
We provide project management for evaluating drug candidates for efficacy and safety in various animals models.
Developability Assessment
Quickly identify the potential risks of manufacture and clinical failure
We offer developability assessment packages to evaluate stability, solubility and specificity to mitigate late-stage risks.
Target Discovery
Lead Generation
In Vitro Bioassay
Lead Optimization
In Vivo Validation
Developability Assessment
Choosing the right target and strategy is the critical decision in your drug development
We provide comprehensive research and customized discovery strategy, based on your target and mechanism of action.
Improve reliability, success rates, and cost-efficiency for lead generation
We use diverse technology (hybridoma, single B cell screening, phage display) to generate more high quality functional leads.
Ensuring functional activity of selected leads for rapid project delivery
We provide a series of HTP cell-based in vitro assays, as part of a comprehensive cell line-based bioassay services offering.
Accelerating the discovery of effective antibody candidates via faster antibody engineering
We provide developability and functionality optimization through comprehensive engineering approaches and project experience.
Gain critical understanding by evaluating preclinical candidates effectively
We provide project management for evaluating drug candidates for efficacy and safety in various animals models.
Quickly identify the potential risks of manufacture and clinical failure
We offer developability assessment packages to evaluate stability, solubility and specificity to mitigate late-stage risks.
Tailored Discovery Strategies across Diverse Biologics Modalities to Maximize Success
ProBio Licenses Rights to SMAB Bispecific Antibody Molecule
ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by ProBio. REMD is a clinical-stage US biotechnology company committed to creating and developing innovative protein-based biologics.
Learn More
Biologics Discovery Service - From Target to Preclinical Candidates
ProBio Biologics Discovery Center leverages over 20 years of expertise in biologics discovery to deliver end‑to‑end services, from target identification to preclinical candidate (PCC) selection. We are committed to accelerating discovery timelines by generating PCCs with strong functionality and optimized developability.
Learn More
Your Faster Biologics Path: Smarter Screening, Faster Development
Single‑domain antibodies (sdAb) are widely used as therapeutics and as building blocks for multispecific antibodies. In the first session, we compare phage display and single B‑cell technologies for sdAb lead generation. The second session highlights our ExpressCMC platform, delivering an industry‑leading four‑month timeline from DNA to tox batch to accelerate CMC development.
Learn More
US
ProBio's GMP Facility in New Jersey
China
ProBio's Flagship in Nanjing
Europe
ProBio's Client Liaison in EMEA
APAC
ProBio in Korea, Japan & Singapore